Filing Flows › C4 Therapeutics (CCCC) › R&D spending
C4 Therapeutics (CCCC) R&D spending by quarter
C4 Therapeutics' R&D spending was $24.8M in Q3 2026 (third quarter 2026), +1% from Q2 2026. Over the last 7 quarters it ranged from $24.5M (Q2 2026) to $27.1M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $24.8M | +1% | -5% |
| Q2 2026 | $24.5M | -0.5% | -7% |
| Q1 2026 | $24.6M | -2% | -9% |
| Q4 2025 | $25.0M | -4% | — |
| Q3 2025 | $26.0M | -0.8% | — |
| Q2 2025 | $26.2M | -3% | — |
| Q1 2025 | $27.1M | — | — |
Q3 2026 at a glance
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is C4 Therapeutics' R&D spending?
C4 Therapeutics' R&D spending was $24.8M in Q3 2026 (third quarter 2026), +1% from Q2 2026.
How has C4 Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $24.5M (Q2 2026) to $27.1M (Q1 2025).